Research & Literature

Approach to lymph node metastases in sporadic medullary thyroid carcinoma An istitutional experience.

Polistena A, Monacelli M, Lucchini R, et al.

Annali italiani di chirurgia 2015; (86()):390-5.

Fine needle aspiration cytology features of poorly differentiated thyroid carcinoma.

Purkait S, Agarwal S, Mathur SR, et al.

Cytopathology : official journal of the British Society for Clinical Cytology 2016; (27(3)):176-84 doi:10.1111/cyt.12270.

Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma.

Kwon H, Kim WG, Sung TY, et al.

Journal of surgical oncology 2016; (113(2)):152-8 doi:10.1002/jso.24126.

Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients' carcinoma death.

Ito Y, Miyauchi A, Kihara M, et al.

Endocrine journal 2016; (63(7)):663-7 doi:10.1507/endocrj.EJ16-0140.

Timing and extension of lymphadenectomy in medullary thyroid carcinoma: A case series from a single institution.

Polistena A, Sanguinetti A, Lucchini R, et al.

International journal of surgery (London, England) 2017; (41 Suppl 1()):S70-S74 doi:10.1016/j.ijsu.2017.04.026.

Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.

Hadoux J, Schlumberger M

Best practice & research. Clinical endocrinology & metabolism 2017; (31(3)):335-347 doi:10.1016/j.beem.2017.04.009.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Subbiah V, Kreitman RJ, Wainberg ZA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(1)):7-13 doi:10.1200/JCO.2017.73.6785.

The Role of Tracheostomy in Anaplastic Thyroid Carcinoma.

Xu J, Liao Z, Li JJ, et al.

World journal of oncology 2015; (6(1)):262-264 doi:10.14740/wjon899w.

Small cell medullary thyroid carcinoma: A diagnostic dilemma.

Verma A, Kane S, Vinarkar S, D'Cruz AK

Indian journal of pathology & microbiology 2017; (60(4)):562-564 doi:10.4103/IJPM.IJPM_187_17.

Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations.

Machens A, Elwerr M, Lorenz K, et al.

The British journal of surgery 2018; (105(2)):e150-e157 doi:10.1002/bjs.10746.

Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer.

Roche AM, Fedewa SA, Shi LL, Chen AY

Cancer 2018; (124(8)):1780-1790 doi:10.1002/cncr.31252.

Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2.

Prete FP, Abdel-Aziz T, Morkane C, et al.

The British journal of surgery 2018; (105(10)):1319-1327 doi:10.1002/bjs.10856.

Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.

Wächter S, Wunderlich A, Greene BH, et al.

International journal of molecular sciences 2018; (19(7)) doi:10.3390/ijms19072077.

Spontaneous Deceleration and Acceleration of Growth Rate in Medullary Thyroid Carcinomas Suggested by Changes in Calcitonin Doubling Times Over Long-Term Surveillance.

Miyauchi A, Kudo T, Kihara M, et al.

World journal of surgery 2019; (43(2)):504-512 doi:10.1007/s00268-018-4789-1.

A somatic mutation of RasGRP3 decreases Na+/I- symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway.

Song J, Qiu W, Deng X, et al.

American journal of cancer research 2018; (8(9)):1847-1855.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Khan SA, Ci B, Xie Y, et al.

Head & neck 2019; (41(6)):1928-1934 doi:10.1002/hed.25634.

An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients.

Huang NS, Shi X, Lei BW, et al.

International journal of endocrinology 2019; (2019()):8428547 doi:10.1155/2019/8428547.

Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.

Duan H, Li Y, Hu P, et al.

Histopathology 2019; (75(6)):890-899 doi:10.1111/his.13942.

Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.

Nikitski AV, Rominski SL, Condello V, et al.

Thyroid : official journal of the American Thyroid Association 2019; (29(10)):1425-1437 doi:10.1089/thy.2019.0284.

Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma.

Wong KS, Lorch JH, Alexander EK, et al.

Thyroid : official journal of the American Thyroid Association 2019; (29(9)):1255-1261 doi:10.1089/thy.2019.0263.

Effect of adjuvant radioactive iodine therapy on survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma).

Yang Q, Zhao Z, Zhong G, et al.

PeerJ 2019; (7()):e7458 doi:10.7717/peerj.7458.

Recent advances and emerging therapies in anaplastic thyroid carcinoma.

Cabanillas ME, Zafereo M, Williams MD, et al.

F1000Research 2018; (7()) doi:10.12688/f1000research.13124.1.

Molecular Alterations in Thyroid Carcinoma.

Haroon Al Rasheed MR, Xu B

Surgical pathology clinics 2019; (12(4)):921-930 doi:10.1016/j.path.2019.08.002.

Updates on the Management of Thyroid Cancer.

Araque KA, Gubbi S, Klubo-Gwiezdzinska J

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2020; (52(8)):562-577 doi:10.1055/a-1089-7870.

PD-1 Blockade in Anaplastic Thyroid Carcinoma.

Capdevila J, Wirth LJ, Ernst T, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(23)):2620-2627 doi:10.1200/JCO.19.02727.

Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.

Chen TY, Lorch JH, Wong KS, Barletta JA

Histopathology 2020; (77(2)):314-320 doi:10.1111/his.14144.

Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.

Al-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J

Cancers 2020; (12(8)) doi:10.3390/cancers12082104.

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

Wirth LJ, Sherman E, Robinson B, et al.

The New England journal of medicine 2020; (383(9)):825-835 doi:10.1056/NEJMoa2005651.

Risk Factors for Lateral Lymph Node Metastases in Patients With Sporadic Medullary Thyroid Carcinoma.

Wu X, Li B, Zheng C, et al.

Technology in cancer research & treatment 2020; (19()):1533033820962089 doi:10.1177/1533033820962089.

Current status of the prognostic molecular markers in medullary thyroid carcinoma.

Oczko-Wojciechowska M, Czarniecka A, Gawlik T, et al.

Endocrine connections 2020; (9(12)):R251-R263.

Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Luo Y, Jiang H, Xu W, et al.

Frontiers in oncology 2020; (10()):549882 doi:10.3389/fonc.2020.549882.

Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.

Arıkan R, Telli TA, Demircan NC, et al.

Current problems in cancer 2021; (45(2)):100668 doi:10.1016/j.currproblcancer.2020.100668.

Results and Clinical Interpretation of Germline RET Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance.

Innella G, Rossi C, Romagnoli M, et al.

Cancers 2020; (12(11)) doi:10.3390/cancers12113268.

Medullary thyroid cancer: What is the optimal management of the lateral neck in a node negative patient at index operation?

Szabo Yamashita T, Rogers RT, Foster TR, et al.

Surgery 2022; (171(1)):177-181 doi:10.1016/j.surg.2021.04.052.

Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [18F]FDG PET/CT.

Ferrari C, Santo G, Ruta R, et al.

Diagnostics (Basel, Switzerland) 2021; (11(8)) doi:10.3390/diagnostics11081417.

The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.

Silver Karcioglu A, Iwata AJ, Pusztaszeri M, et al.

Cancer cytopathology 2022; (130(3)):174-180 doi:10.1002/cncy.22519.

State of the art and future directions in the systemic treatment of medullary thyroid cancer.

Jager EC, Broekman KE, Kruijff S, Links TP

Current opinion in oncology 2022; (34(1)):1-8 doi:10.1097/CCO.0000000000000798.

Anaplastic Thyroid Carcinoma: An Update.

Jannin A, Escande A, Al Ghuzlan A, et al.

Cancers 2022; (14(4)) doi:10.3390/cancers14041061.

Unraveling Hürthle cell lesions of the thyroid using molecular findings.

Wong KS

Cancer cytopathology 2022; (130(6)):405-406 doi:10.1002/cncy.22567.

Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Baloch ZW, Asa SL, Barletta JA, et al.

Endocrine pathology 2022; (33(1)):27-63 doi:10.1007/s12022-022-09707-3.

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

Waguespack SG, Drilon A, Lin JJ, et al.

European journal of endocrinology 2022; (186(6)):631-643 doi:10.1530/EJE-21-1259.

Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?

Juhlin CC

Cancer drug resistance (Alhambra, Calif.) 2020; (3(4)):992-1000 doi:10.20517/cdr.2020.66.

"Triple-negative" non-secretory medullary thyroid cancer: uncommon pathological findings in a rare disease.

Martínez-Montoro JI, Gómez-Pérez AM, Gallego E, et al.

Archives of medical science : AMS 2022; (18(3)):825-828 doi:10.5114/aoms/147431.

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Haddad RI, Bischoff L, Ball D, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(8)):925-951.

Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.

Maurer E, Eilsberger F, Wächter S, et al.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2023; (280(3)):1509-1518 doi:10.1007/s00405-023-07827-y.

Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.

Treglia G, Rufini V, Piccardo A, Imperiale A

Seminars in nuclear medicine 2023; (53(4)):481-489 doi:10.1053/j.semnuclmed.2023.01.003.

No Longer Well-Differentiated: Diagnostic Criteria and Clinical Importance of Poorly Differentiated/High-Grade Thyroid Carcinoma.

Cracolici V

Surgical pathology clinics 2023; (16(1)):45-56 doi:10.1016/j.path.2022.09.006.

Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer.

Li W, Li Y, Li J, Pang H

Technology in cancer research & treatment 2023; (22()):15330338231169870 doi:10.1177/15330338231169870.

Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma.

Gopal RK, Vantaku VR, Panda A, et al.

Cancer discovery 2023; (13(8)):1904-1921 doi:10.1158/2159-8290.CD-22-0976.

Incidence and Clinicopathological Features of Differentiated High-Grade Thyroid Carcinomas: An Institutional Experience.

Jeong SI, Kim W, Yu HW, et al.

Endocrine pathology 2023; (34(3)):287-297 doi:10.1007/s12022-023-09778-w.

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

Hadoux J, Elisei R, Brose MS, et al.

The New England journal of medicine 2023; (389(20)):1851-1861 doi:10.1056/NEJMoa2309719.

Liver Mass as First-Time Diagnosis of Sarcomatoid Anaplastic Thyroid Carcinoma: A Rare Malignancy Presenting at an Unexpected Body Site.

Kamashki A, Rivera M, Sturgis CD

The American journal of case reports 2023; (24()):e941838 doi:10.12659/AJCR.941838.

Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.

Shen H, Zhu R, Liu Y, et al.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2024; (72()):101013 doi:10.1016/j.drup.2023.101013.

Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.

Bischoff LA, Ganly I, Fugazzola L, et al.

JAMA otolaryngology-- head & neck surgery 2024; (150(3)):265-272 doi:10.1001/jamaoto.2023.4323.

Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.

Ghossein R, Katabi N, Dogan S, et al.

Histopathology 2024; (84(7)):1130-1138 doi:10.1111/his.15157.

Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.

Liu S, Zhao H, Li X

Cancer management and research 2024; (16()):299-310 doi:10.2147/CMAR.S440477.

Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan.

Toda S, Hiroshima Y, Iwasaki H, Masudo K

The Journal of clinical endocrinology and metabolism 2024; (109(11)):2784-2792 doi:10.1210/clinem/dgae271.

WHO 2022 updates on follicular cell and c-cell derived thyroid neoplasm.

Goswami P, Patel T, Dave R, et al.

Journal of medicine and life 2024; (17(1)):15-23 doi:10.25122/jml-2023-0270.

[30 years of prophylactic thyroidectomy for hereditary medullary thyroid cancer : A milestone in translational medicine].

Dralle H, Weber F, Lorenz K, Machens A

Chirurgie (Heidelberg, Germany) 2024; (95(8)):638-650 doi:10.1007/s00104-024-02105-x.

Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.

Abdalla AS, Rahman M, Khan SA

Current treatment options in oncology 2024; (25(7)):869-884 doi:10.1007/s11864-024-01219-y.

A Comprehensive Review and Insights into the New Entity of Differentiated High-Grade Thyroid Carcinoma.

Harahap AS, Roren RS, Imtiyaz S

Current oncology (Toronto, Ont.) 2024; (31(6)):3311-3328 doi:10.3390/curroncol31060252.

Management of Poorly Differentiated Thyroid Cancer and Differentiated High-Grade Thyroid Carcinoma.

Alam IS, Patel KN

The Surgical clinics of North America 2024; (104(4)):751-765 doi:10.1016/j.suc.2024.02.005.

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.

Hamidi S, Dadu R, Zafereo ME, et al.

JAMA oncology 2024; (10(9)):1264-1271 doi:10.1001/jamaoncol.2024.2133.

Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.

Barbaro D, Forleo R, Profilo MA, et al.

Frontiers in endocrinology 2024; (15()):1389294 doi:10.3389/fendo.2024.1389294.

An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Behnagh AK, Eghbali M, Abdolmaleki F, et al.

Iranian journal of public health 2024; (53(7)):1496-1507 doi:10.18502/ijph.v53i7.16044.

[18F]TFB PET/CT misses intense [124I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.

Backhaus P, Pentlow KS, Ho AL, et al.

EJNMMI research 2024; (14(1)):91 doi:10.1186/s13550-024-01138-x.

Aggressive Types of Malignant Thyroid Neoplasms.

Boudina M, Zisimopoulou E, Xirou P, Chrisoulidou A

Journal of clinical medicine 2024; (13(20)) doi:10.3390/jcm13206119.

Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management.

Mete O, Boucher A, Schrader KA, et al.

Endocrine pathology 2024; (35(4)):293-308 doi:10.1007/s12022-024-09836-x.

The Role of CD56, HBME-1, and CK19 Immunohistochemical Markers in the differential Diagnosing of Thyroid Neoplasms.

Chandrakumari AS, Singaravelu SLD, Sinha P

Nigerian medical journal : journal of the Nigeria Medical Association 2024; (65(5)):716-724 doi:10.60787/nmj-v65i3.509.

Could SLC26A7 Be a Promising Marker for Preoperative Diagnosis of High-Grade Papillary Thyroid Carcinoma?

Titov SE, Kozorezova ES, Lukyanov SA, et al.

Diagnostics (Basel, Switzerland) 2024; (14(23)) doi:10.3390/diagnostics14232652.

Insights into Thyroid and Salivary Gland Cytopathology: Highlights from a 45th European Congress of Cytology Slide Seminar.

Brochard C, Kowalewski A, Vigliar E, et al.

Acta cytologica 2025; (69(2)):171-182 doi:10.1159/000543225.

Diagnostics and treatment of differentiated thyroid carcinoma in children - Guidelines of the Polish National Scientific Societies, 2024 Update.

Handkiewicz-Junak D, Niedziela M, Lewiński A, et al.

Endokrynologia Polska 2024; (75(6)):565-591 doi:10.5603/ep.103845.

Modern Therapeutic Approaches in Anaplastic Thyroid Cancer: A Meta-Analytic Review of Randomised and Single Arm Studies on Efficacy and Survival.

Tunio MA, Hinder D, Emery B, et al.

Cancers 2025; (17(5)) doi:10.3390/cancers17050777.

Histopathology of C Cells and Medullary Thyroid Carcinoma.

Cameselle-Teijeiro JM, Sobrinho-Simões M

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2025; (223()):9-50 doi:10.1007/978-3-031-80396-3_2.

Anticancer drug therapy for anaplastic thyroid cancer.

Kiyota N, Koyama T, Sugitani I

European thyroid journal 2025; (14(2)).

The ability of anexelekto (AXL) expression and TERT promoter mutation to predict radioiodine-refractory differentiated thyroid carcinoma.

Agustina H, Ayni TN, Azhar Y, et al.

Diagnostic pathology 2025; (20(1)):46 doi:10.1186/s13000-025-01643-0.

Comparative analysis of follicular cell- derived thyroid carcinoma: assessing the impact of high-grade features in an advanced disease cohort.

Caldeira M, Canberk S, Macedo S, et al.

Virchows Archiv : an international journal of pathology 2025; (486(6)):1305-1315 doi:10.1007/s00428-025-04109-2.

Endocrine and Neuroendocrine Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book".

Hernandez-Prera JC, Riddle N, Gonzalez RS, Asa SL

Archives of pathology & laboratory medicine 2025; (149(12)):1114-1135 doi:10.5858/arpa.2024-0315-RA.

Systemic therapies for medullary thyroid carcinoma: state of the art.

Román-González A, Califano I, Concepción-Zavaleta M, et al.

Therapeutic advances in endocrinology and metabolism 2025; (16()):20420188251336091 doi:10.1177/20420188251336091.

Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review.

Schipor S, Publik MA, Manda D, Ceausu M

International journal of molecular sciences 2025; (26(12)) doi:10.3390/ijms26125535.

The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.

Moon S, Song YS, Jung KY, et al.

Endocrinology and metabolism (Seoul, Korea) 2025; (40(3)):357-384 doi:10.3803/EnM.2025.2465.

Role of TERT gene mutation in the pathogenesis of anaplastic thyroid carcinoma (Review).

Alhejaily AG, Alhuzaim O, Aljohani N, et al.

Molecular and clinical oncology 2025; (23(2)):74 doi:10.3892/mco.2025.2869.

NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025.

Haddad RI, Bischoff L, Applewhite M, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2025; (23(7)).

Remarkable Response to Chemo-immunotherapy In Anaplastic Thyroid Cancer.

Carosi F, Nigro MC, Siepe G, et al.

JCEM case reports 2025; (3(9)):luaf160 doi:10.1210/jcemcr/luaf160.

Gene Expression Analysis of Papillary Thyroid Carcinoma With Lymph Node Metastasis and Radioiodine Refractivity.

Mohamad Pakarulrazy NF, Abu N, Abdullah Suhaimi SN, et al.

Cureus 2025; (17(6)):e87001 doi:10.7759/cureus.87001.

Mutational Profiling Detection in FNAC Samples of Different Types of Thyroid Neoplasms Using Targeted NGS.

Liang R, Luo M, Yang X, et al.

Cancers 2025; (17(15)) doi:10.3390/cancers17152429.

TGF-β1-based restoration of sodium iodide symporter expression in radioiodine-refractory differentiated thyroid cancer via engineered MSCs.

Han Y, Koehler VF, Nagarajah J, et al.

Molecular therapy : the journal of the American Society of Gene Therapy 2025; (33(12)):6130-6145 doi:10.1016/j.ymthe.2025.10.033.

Characterizing thyroid carcinomas in the elderly: Histological subtypes and TERT promoter mutation analysis based on the latest WHO classification.

Koh MJ, Noh S, Kim JK, Kim GJ

Annals of diagnostic pathology 2026; (80()):152578 doi:10.1016/j.anndiagpath.2025.152578.

Somatic genetic alterations in the development and progression in thyroid tumors of follicular cells.

Calafato G, Di Paola FJ, De Leo A, et al.

European thyroid journal 2025; (14(5)).

RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.

Ricciardi Tenore C, Tulli E, Perrucci A, et al.

Genes 2025; (16(12)) doi:10.3390/genes16121472.

SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.

Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, et al.

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2026; (59(2)):100859 doi:10.1016/j.patol.2026.100859.